Vanguard Fiduciary Trust
ALGS icon

Vanguard Fiduciary Trust’s Aligos Therapeutics ALGS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio ALGS Stock Details ALGS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$165K Buy
28,612
+175
+0.6% +$1.08K ﹤0.01% 3630
2026
Q1 		$211K Buy
+28,437
New +$216K ﹤0.01% 3506

Other funds holding ALGS

DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
SCM
Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Vanguard Fiduciary Trust's ALGS Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Aligos Therapeutics (ALGS) stake by 0.62% in Q2 2026, buying an estimated $1.08K and bringing the position to 28,612 shares worth $165K. The position accounts for ﹤0.01% of the portfolio, ranked #3630.

Vanguard Fiduciary Trust first reported a position in ALGS in Q1 2026 and has held it in 2 quarters since. The position peaked at $211K in Q1 2026. 31 funds tracked by Wall St. Rank hold ALGS as of Q2 2026.

  • Vanguard Fiduciary Trust held 28,612 shares of Aligos Therapeutics worth $165K as of Q2 2026.
  • Vanguard Fiduciary Trust bought 175 Aligos Therapeutics shares in Q2 2026, an estimated $1.08K.
  • Aligos Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3630 holding.
  • Vanguard Fiduciary Trust first reported a position in Aligos Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Aligos Therapeutics position peaked at $211K in Q1 2026.
  • 31 funds tracked by Wall St. Rank held Aligos Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.